228 related articles for article (PubMed ID: 18975354)
41. Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?
Buch MH; Emery P
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):288-9. PubMed ID: 16932704
[No Abstract] [Full Text] [Related]
42. The use of glucocorticoids in preventing joint destruction: Comment on the review by Schett et al.
Kirwan JR; Boers Msc M
Arthritis Rheum; 2009 Apr; 60(4):1202-3; reply 1203-4. PubMed ID: 19333941
[No Abstract] [Full Text] [Related]
43. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.
Musacchio E; Valvason C; Botsios C; Ostuni F; Furlan A; Ramonda R; Modesti V; Sartori L; Punzi L
J Rheumatol; 2009 Aug; 36(8):1575-9. PubMed ID: 19567627
[TBL] [Abstract][Full Text] [Related]
44. Designing micro- and nano-particles for treating rheumatoid arthritis.
Mitragotri S; Yoo JW
Arch Pharm Res; 2011 Nov; 34(11):1887-97. PubMed ID: 22139688
[TBL] [Abstract][Full Text] [Related]
45. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
46. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
Wang BL; Zheng F; Qiu MC
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
[TBL] [Abstract][Full Text] [Related]
47. Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial Fibroblasts.
Watanabe T; Takahashi N; Hirabara S; Ishiguro N; Kojima T
PLoS One; 2016; 11(4):e0153142. PubMed ID: 27054952
[TBL] [Abstract][Full Text] [Related]
48. Re: Rheumatoid arthritis and fibromyalgia: a frequent unrelated association complicating disease management.
St Amand RP
J Rheumatol; 2009 Sep; 36(9):2124; discussion 2124-5. PubMed ID: 19738226
[No Abstract] [Full Text] [Related]
49. SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes.
Keller KK; Lindgaard LM; Wogensen L; Dagnæs-Hansen F; Thomsen JS; Sakaguchi S; Stengaard-Pedersen K; Hauge EM
Rheumatol Int; 2013 May; 33(5):1127-33. PubMed ID: 22948540
[TBL] [Abstract][Full Text] [Related]
50. Management of associated rheumatoid arthritis and fibromyalgia.
Pincus T
J Rheumatol; 2009 Sep; 36(9):2123-4; discussion 2124-5. PubMed ID: 19738225
[No Abstract] [Full Text] [Related]
51. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.
Riksen NP; Rongen GA; Smits P; van Riel P; Barrera P
Arthritis Rheum; 2007 Feb; 56(2):694; author reply 694-5. PubMed ID: 17265507
[No Abstract] [Full Text] [Related]
52. Erosive arthritis.
Schett G
Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S2. PubMed ID: 17634141
[TBL] [Abstract][Full Text] [Related]
53. Increased adiponectin levels in women with rheumatoid arthritis after etanercept treatment.
Lewicki M; Kotyla P; Kucharz E
J Rheumatol; 2009 Jun; 36(6):1346-7; author reply 1347. PubMed ID: 19509093
[No Abstract] [Full Text] [Related]
54. Comment on high HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
Dullaart RP
Eur J Clin Invest; 2009 Jun; 39(6):533. PubMed ID: 19490063
[No Abstract] [Full Text] [Related]
55. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients.
Wijbrandts CA; Remans PH; Klarenbeek PL; Wouters D; van den Bergh Weerman MA; Smeets TJ; Vervoordeldonk MJ; Baeten D; Tak PP
Arthritis Rheum; 2008 Nov; 58(11):3330-9. PubMed ID: 18975323
[TBL] [Abstract][Full Text] [Related]
56. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
McGonigle JS; Giachelli CM; Scatena M
Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
[TBL] [Abstract][Full Text] [Related]
57. [Treatment strategy for rheumatoid arthritis in Croatia].
Curković B
Reumatizam; 2008; 55(2):39-44. PubMed ID: 19024273
[TBL] [Abstract][Full Text] [Related]
58. Challenges of predicting treatment response in patients with rheumatoid arthritis.
Smolen JS; Aletaha D
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):62-3. PubMed ID: 16932630
[No Abstract] [Full Text] [Related]
59. Stromal cell-derived factor 1-induced osteoclast differentiation independent of RANKL: comment on the article by Kim et al.
Ji JD
Arthritis Rheumatol; 2014 Oct; 66(10):2911. PubMed ID: 24981127
[No Abstract] [Full Text] [Related]
60. Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al.
Kirwan JR
Arthritis Rheum; 1999 May; 42(5):1066-7. PubMed ID: 10323469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
